Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 16/20 | 0.86 |
| ▸ | ERBB2 known ✓ | P04626 | 15/20 | 0.86 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.74 |
| ▸ | INSR known ✓ | P06213 | 1/20 | 0.74 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.74 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.87 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.74 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.74 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.74 |
| ▸ | STK10 | O94804 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.74 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.74 |
| ▸ | CDK2 | P24941 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15767655 | 0.96 | ABCB11 (0.89) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL93590 | 0.93 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29866632 | 0.93 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL31732815 | 0.93 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL1374543 | 0.93 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| SCHEMBL15765992 | 0.93 | EGFR (0.84) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL571898 | 0.92 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29356338 | 0.92 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL30680457 | 0.92 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL4926017 | 0.92 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740729-B1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RES (CN) | 2020-11-25 | — | — | EP | claimed |
| US-9499530-B2 | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCH (CN) | 2016-11-22 | — | — | US | claimed |
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD (CN) | 2015-03-19 | — | — | US | claimed |
| EP-2740729-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | Hangzhou Minsheng Institutes for Pharma Research (CN) | 2014-06-11 | — | — | EP | claimed |
| EP-2740729-B1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RES (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-9499530-B2 | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCH (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| EP-2740729-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | Hangzhou Minsheng Institutes for Pharma Research (CN) | 2014-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | LCK, ZAP70, FYN | EGFR 24/4885ERBB2 6/4885ABL1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.